U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H20N2O3S.ClH
Molecular Weight 392.9014
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIOGLITAZONE HYDROCHLORIDE

SMILES

CCc1ccc(CCOc2ccc(cc2)CC3C(=NC(=O)S3)O)nc1.Cl

InChI

InChIKey=GHUUBYQTCDQWRA-UHFFFAOYSA-N
InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://reference.medscape.com/drug/actos-pioglitazone-342726 | https://www.drugbank.ca/drugs/DB01132 | https://www.drugs.com/cdi/pioglitazone.html | https://www.ncbi.nlm.nih.gov/pubmed/25760794

Pioglitazone (brand name Actos) is a prescription drug of the thiazolidinedione class with hypoglycemic action used in the treatment of type 2 diabetes. Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. It modulates the transcription of the genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues, decreases gluconeogenesis in the liver, and reduces the quantity of glucose and glycated hemoglobin in the bloodstream. Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin, or insulin. Pioglitazone cannot be used in patients with a known hypersensitivity to pioglitazone, other thiazolidinediones or any of components of its pharmaceutical forms. It is ineffective and possibly harmful to diabetes mellitus type 1 and diabetic ketoacidosis. Pioglitazone can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on pioglitazone had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems.

Originator

Curator's Comment:: # Takeda Chemical Industries, Ltd

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

9.3199683E11
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

9.3199683E11
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

9.3199683E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
890 ng/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
8662 ng × h/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.6 h
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
0.75 mg/kg 1 times / day multiple, oral
MTD
Dose: 0.75 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.75 mg/kg, 1 times / day
Sources: Page: p.7, 9
unhealthy, 5-12
n = 18
Health Status: unhealthy
Condition: Autistic disorder|Asperger syndrome
Age Group: 5-12
Sex: M+F
Population Size: 18
Sources: Page: p.7, 9
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Disc. AE: Edema, ALT increased...
AEs leading to
discontinuation/dose reduction:
Edema (mild, 1.67%)
ALT increased (grade 2-4, 1.67%)
Sources: Page: p.983, 984
180 mg 1 times / day multiple, oral
Overdose
Dose: 180 mg, 1 times / day
Route: oral
Route: multiple
Dose: 180 mg, 1 times / day
Sources: Page: p.21
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.21
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Disc. AE: Congestive heart failure, Edema...
AEs leading to
discontinuation/dose reduction:
Congestive heart failure
Edema
Hepatic failure (grade 5)
Fractures
Bladder cancer
Hypoglycemia
Macular edema
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
ALT increased grade 2-4, 1.67%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Edema mild, 1.67%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Bladder cancer Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Congestive heart failure Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Edema Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Fractures Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Hypoglycemia Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Macular edema Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Hepatic failure grade 5
Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition.
2006 Aug
Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat.
2006 Aug 29
Rosiglitazone inhibits mouse liver regeneration.
2006 Dec
[Resveratrol inhibits expression of EMMPRIN from macrophages].
2006 Jul
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
2006 Jul
Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation.
2006 Jul
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
2006 Jun
Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening.
2006 Mar-Apr
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis.
2006 May
The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
2006 Nov 7
Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
2006 Oct
Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma.
2006 Oct 15
Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.
2007
Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma.
2007 Feb
Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.
2007 Jan
Effect of pioglitazone treatment on behavioral symptoms in autistic children.
2007 Jan 5
[Effects of peroxisome proliferators activated receptors on caveolin-1 expression in foam cells].
2007 Jul
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
2007 Jul
Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines.
2007 Mar
Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.
2007 May
Inhibitory effect of PPAR on the expression of EMMPRIN in macrophages and foam cells.
2007 May 2
NR4A orphan nuclear receptors modulate insulin action and the glucose transport system: potential role in insulin resistance.
2007 Oct 26
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
2007 Sep 12
MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone.
2007 Sep 4
Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?
2008 Apr
Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
2008 Feb
Treating Hispanic patients for type 2 diabetes mellitus: special considerations.
2008 May
JNK- and IkappaB-dependent pathways regulate MCP-1 but not adiponectin release from artificially hypertrophied 3T3-L1 adipocytes preloaded with palmitate in vitro.
2008 May
Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line.
2008 Oct
Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes.
2008 Sep
Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding.
2009
Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro.
2009 Apr
Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes.
2009 Apr
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
2009 Aug
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
2009 Dec 3
Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.
2009 Jan
Retinol saturase promotes adipogenesis and is downregulated in obesity.
2009 Jan 27
Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver.
2009 Mar
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
2009 May
Emerging treatments in cystic fibrosis.
2009 Oct 1
Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.
2009 Oct 30
Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
2010 Apr 15
Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.
2010 Aug
Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.
2010 Feb
Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
2010 Jul 9
Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene.
2010 Jun
Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.
2010 May
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
2010 May
Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.
2010 Oct 6
Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.
2010 Sep 25
Patents

Sample Use Guides

Initiate ACTOS (Pioglitazone) at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily.
Route of Administration: Oral
For the cell counting assay, Human aortic smooth muscle cells (HASMCs) were seeded at 3× 10^3 cells on to a 96-well dish; 24 hours after the plating, the cells were serum-starved to render them quiescent by replacing the medium with DMEM containing 0.2% FBS. The quiescent SMCs were then preincubated with globular adiponectin (1μg/mL or 3μg/mL) or pioglitazone (1μM or 10μM) for 30min. PDGF-BB (10ng/mL) was added to stimulate the cells for 24hours. These cells were incubated with 10 μl of CCK (cell counting kit)-8 (DOJINDO) or WST-1 (Roche) solution for 2hours before conducting the measurements. We measured the absorbance at 450nm using a microplate reader. 10 μl of BrdU (Roche) solution was added these cells simultaneously with PDGF-BB. BrdU incorporation was measured by chemiluminescent assay
Name Type Language
PIOGLITAZONE HYDROCHLORIDE
JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
PIOGLITAZONE HYDROCHLORIDE [USAN]
Common Name English
PIOGLITAZONE HCL
VANDF  
Common Name English
PIOMED
Brand Name English
PIOGLITAZONE HYDROCHLORIDE COMPONENT OF OSENI
Brand Name English
OSENI COMPONENT PIOGLITAZONE HYDROCHLORIDE
Brand Name English
PIOGLITAZONE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
PIOGLITAZONE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
ACTOS
Brand Name English
PIOGLITAZONE HYDROCHLORIDE [WHO-DD]
Common Name English
PIOGLITAZONE HYDROCHLORIDE COMPONENT OF ACTOPLUS MET
Common Name English
NSC-758876
Code English
PIOGLITAZONE (AS HYDROCHLORIDE)
Common Name English
PIOGLITAZONE HYDROCHLORIDE [MI]
Common Name English
PIOGLITAZONE HYDROCHLORIDE COMPONENT OF DUETACT
Common Name English
PIOGLITAZONE HCL [VANDF]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-, MONOHYDROCHLORIDE, (+/-)-
Common Name English
PIOGLITAZONE HYDROCHLORIDE [JAN]
Common Name English
U-72107A
Code English
PIOGLITAZONE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
ACTOPLUS MET COMPONENT PIOGLITAZONE HYDROCHLORIDE
Common Name English
STR-001
Code English
PIOGLITAZONE HYDROCHLORIDE [MART.]
Common Name English
PIOGLITAZONE HYDROCHLORIDE [USP-RS]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
(+/-)-5-(P-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE MONOHYDROCHLORIDE
Common Name English
PIOGLITAZONE HYDROCHLORIDE [VANDF]
Common Name English
DUETACT COMPONENT PIOGLITAZONE HYDROCHLORIDE
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-, MONOHYDROCHLORIDE
Common Name English
POZE
Brand Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/16/1823
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
NCI_THESAURUS C98241
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
Code System Code Type Description
USP_CATALOG
1539905
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C29367
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY
DRUG BANK
DBSALT000555
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY
PUBCHEM
60560
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY
MERCK INDEX
M8835
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL595
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY
CAS
112529-15-4
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY
EVMPD
SUB03834MIG
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY
FDA UNII
JQT35NPK6C
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY
EPA CompTox
112529-15-4
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY
CAS
127676-30-6
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
SUPERSEDED
RXCUI
259319
Created by admin on Fri Jun 25 21:06:37 UTC 2021 , Edited by admin on Fri Jun 25 21:06:37 UTC 2021
PRIMARY RxNorm